Anton Pottegård1, Anne Broe1, Jesper Hallas2, Ove B Schaffalitzky de Muckadell3, Annmarie T Lassen4, Anders B Lødrup5. 1. Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark. 2. Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark Department of Clinical Chemistry & Pharmacology, Odense University Hospital. 3. Department of Medical Gastroenterology, Odense University Hospital, Denmark. 4. Department of Emergency Medicine, Odense University Hospital, Denmark. 5. Department of Hepatology and Gastroenterology, Aarhus University Hospital, Nørrebrogade 44, Aarhus, 8000, Denmark.
Abstract
BACKGROUND: The use of proton-pump inhibitors (PPIs) has increased over the last decade. The objective of this study was to provide detailed utilization data on PPI use over time, with special emphasis on duration of PPI use and concomitant use of ulcerogenic drugs. METHODS: Using the nationwide Danish Prescription Registry, we identified all Danish adults filling a PPI between 2002 and 2014. Using descriptive statistics, we reported (i) the distribution of use between single PPI entities, (ii) the development in incidence and prevalence of use over time, (iii) measures of duration and intensity of treatment, and (iv) the prevalence of use of ulcerogenic drugs among users of PPIs. RESULTS: We identified 1,617,614 adults using PPIs during the study period. The prevalence of PPI use increased fourfold during the study period to 7.4% of all Danish adults in 2014. PPI use showed strong age dependency, reaching more than 20% among those aged at least 80 years. The proportion of users maintaining treatment over time increased with increasing age, with less than10% of those aged 18-39 years using PPIs 2 years after their first prescription, compared with about 40% among those aged at least 80 years. The overall use of ulcerogenic drugs among PPI users increased moderately, from 35% of users of PPI in 2002 to 45% in 2014. CONCLUSIONS: The use of PPIs is extensive and increasing rapidly, especially among the elderly.
BACKGROUND: The use of proton-pump inhibitors (PPIs) has increased over the last decade. The objective of this study was to provide detailed utilization data on PPI use over time, with special emphasis on duration of PPI use and concomitant use of ulcerogenic drugs. METHODS: Using the nationwide Danish Prescription Registry, we identified all Danish adults filling a PPI between 2002 and 2014. Using descriptive statistics, we reported (i) the distribution of use between single PPI entities, (ii) the development in incidence and prevalence of use over time, (iii) measures of duration and intensity of treatment, and (iv) the prevalence of use of ulcerogenic drugs among users of PPIs. RESULTS: We identified 1,617,614 adults using PPIs during the study period. The prevalence of PPI use increased fourfold during the study period to 7.4% of all Danish adults in 2014. PPI use showed strong age dependency, reaching more than 20% among those aged at least 80 years. The proportion of users maintaining treatment over time increased with increasing age, with less than10% of those aged 18-39 years using PPIs 2 years after their first prescription, compared with about 40% among those aged at least 80 years. The overall use of ulcerogenic drugs among PPI users increased moderately, from 35% of users of PPI in 2002 to 45% in 2014. CONCLUSIONS: The use of PPIs is extensive and increasing rapidly, especially among the elderly.
Authors: Neena S Abraham; Mark A Hlatky; Elliott M Antman; Deepak L Bhatt; David J Bjorkman; Craig B Clark; Curt D Furberg; David A Johnson; Charles J Kahi; Loren Laine; Kenneth W Mahaffey; Eamonn M Quigley; James Scheiman; Laurence S Sperling; Gordon F Tomaselli Journal: J Am Coll Cardiol Date: 2010-12-07 Impact factor: 24.094
Authors: Michael Dall; Ove B Schaffalitzky de Muckadell; Annmarie Touborg Lassen; Jane Møller Hansen; Jesper Hallas Journal: Clin Gastroenterol Hepatol Date: 2009-08-26 Impact factor: 11.382
Authors: Daniel Pilsgaard Henriksen; Jesper Rømhild Davidsen; Christian B Laursen; Anders Christiansen; Per Damkier; Jesper Hallas; Anton Pottegård Journal: Eur J Clin Pharmacol Date: 2017-06-22 Impact factor: 2.953
Authors: Chandan Vangala; Jingbo Niu; Colin R Lenihan; William E Mitch; Sankar D Navaneethan; Wolfgang C Winkelmayer Journal: Clin J Am Soc Nephrol Date: 2018-09-27 Impact factor: 8.237